Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at one-tenth of the original cost.

in India. The drug has been introduced under the brand name Glempa (empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (empagliflozin 10/25 mg + linagliptin 5 mg) and ...

Glenmark Pharmaceuticals announced that it has launched generic Empagliflozin, a widely recognized SGLT2 inhibitor, in India.

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Mankind Pharma on Wednesday said it has launched a generic version of diabetes medication Empagliflozin in the country.      The company has launched Empagliflozin tablets under brand names Empaglyde, ...

in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg ...

Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, following the expiry of its patent. Estimated to significantly cut costs and ...

in India. “Mankind is launching this product at approximately 90 percent discount. By introducing Empagliflozin at INR 5.49 per tablet for the 10 mg variant and INR 9.90 per tablet for the 25 mg ...

German pharmaceutical company Boehringer Ingelheim’s diabetes drug empagliflozin went off patent on Tuesday, and India's top generics ... would be approximately 5 to 6 times more than whatever ...